India’s Hetero Wins Approval To Launch COVID-19 Drug Favipiravir

India’s Hetero Labs Ltd said it received local regulatory approval to launch its version of anti-viral drug favipiravir for the treatment of COVID-19.

The drug, priced at 59 rupees (79 US cents) per tablet, will be available at drug stores from Wednesday, privately held Hetero said.

Recommended for you